Tara Brown, NP
Family · Lavonia, GANPI 1952728651
Payments from drug & device makers
Across 118 payments — averaging $16.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$547
- Shield Therapeutics Inc$254
- Otsuka America Pharmaceutical, Inc.$211
- Novo Nordisk$208
- Pfizer$124
- AstraZeneca$92
- plus $524 from 19 others
What the payments were for
- Food & beverage$1,959100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 50 | $547 |
| Shield Therapeutics Inc | 6 | $254 |
| Otsuka America Pharmaceutical, Inc. | 9 | $211 |
| Novo Nordisk | 11 | $208 |
| Pfizer | 7 | $124 |
| AstraZeneca | 5 | $92 |
| GSK | 4 | $61 |
| Lundbeck LLC | 3 | $56 |
| Exact Sciences | 3 | $50 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $37 |
| Dexcom, Inc. | 2 | $36 |
| Abbott | 2 | $32 |
| Lilly USA, LLC | 2 | $30 |
| Vertex | 1 | $23 |
| Axsome Therapeutics, Inc. | 1 | $21 |
| Boehringer Ingelheim | 1 | $20 |
| Amgen | 1 | $20 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $20 |
| Johnson & Johnson | 1 | $19 |
| Boston Scientific | 1 | $19 |
| Sanofi-aventis U.S. LLC | 1 | $18 |
| Bayer | 1 | $18 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $18 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| Biohaven Pharmaceuticals, Inc. | 1 | $12 |
How this compares
$1,959 in reported general payments places this provider in the 80th percentile of 6,258 family providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 15 | $24,730 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 26 | $21,200 |
| EliquisApixaban | 20 | $20,677 |
| JardianceEmpagliflozin | 25 | $15,894 |
| JanuviaSitagliptin Phosphate | 11 | $12,884 |
| FarxigaDapagliflozin Propanediol | 14 | $8,094 |
| LinzessLinaclotide | 13 | $7,859 |
| TrintellixVortioxetine Hydrobromide | 13 | $6,271 |
| Tresiba Flextouch U-100Insulin Degludec | 11 | $5,599 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 12 | $5,460 |
| Arnuity ElliptaFluticasone Furoate | 12 | $2,355 |
| Famotidine | 80 | $1,932 |
| Gabapentin | 120 | $1,885 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 78 | $1,640 |
| Hydroxyzine Hcl | 32 | $1,140 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $208 | $24,73015 claims |
| GSKTrelegy Ellipta, Arnuity Ellipta | $61 | $23,55538 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat | $20 | $21,35437 claims |
| PfizerEliquis | $124 | $20,67720 claims |
| AstraZenecaFarxiga | $92 | $8,09414 claims |
| AbbVieLinzess | $547 | $7,85913 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $37 | $6,27113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 6,258 family providers in Georgia.
Other family in Lavonia
- Allie McAllisterMarietta$299K
- Tonita WashingtonLawrenceville$153K
- Erin HenryLawrenceville$135K
- Trisha RomanPeachtree City$134K
- Lori ReedMarietta$106K
- Julia BranchCumming$102K
- Hannah BanachWaycross$85K
- Morgan GroothandEvans$81K
- Anna Carolina WrightLilburn$69K
- Jessica FeehanCanton$51K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.